Glenmark Life Sciences Limited
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and m… Read more
Glenmark Life Sciences Limited - Asset Resilience Ratio
Glenmark Life Sciences Limited (GLS) has an Asset Resilience Ratio of 2.73% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2024)
This chart shows how Glenmark Life Sciences Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Glenmark Life Sciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₹0.00 | 0% |
| Short-term Investments | ₹840.85 Million | 2.73% |
| Total Liquid Assets | ₹840.85 Million | 2.73% |
Asset Resilience Insights
- Limited Liquidity: Glenmark Life Sciences Limited maintains only 2.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Glenmark Life Sciences Limited Industry Peers by Asset Resilience Ratio
Compare Glenmark Life Sciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biostar Pharmaceuticals Inc
PINK:BSPM |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
High Sierra Technologies Inc
PINK:HSTI |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
Annual Asset Resilience Ratio for Glenmark Life Sciences Limited (2019–2024)
The table below shows the annual Asset Resilience Ratio data for Glenmark Life Sciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-03-31 | 3.18% | ₹905.48 Million | ₹28.50 Billion | -0.39pp |
| 2023-03-31 | 3.57% | ₹964.78 Million | ₹27.02 Billion | +3.36pp |
| 2022-03-31 | 0.21% | ₹51.46 Million | ₹24.71 Billion | -1.00pp |
| 2021-03-31 | 1.21% | ₹241.64 Million | ₹19.97 Billion | +0.01pp |
| 2020-03-31 | 1.20% | ₹207.70 Million | ₹17.26 Billion | +0.81pp |
| 2019-03-31 | 0.39% | ₹57.87 Million | ₹14.75 Billion | -- |